ArticleLangenbeck's archives of surgery2025
Segmentectomy is associated with worse disease-free survival compared to lobectomy in patients with stage IA3 non-small cell lung cancer.
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Local Recurrence After Lung Segmentectomy-Risk Factors and Future Directions: A Contemporary Review.Cancers · 2026Review
- Postoperative rupture of bronchial stump inducing severe hemorrhage from pulmonary artery trunk: a case report.Journal of cardiothoracic surgery · 2026Article
- Oncological Outcome of Minimally Invasive Single-Port Segmentectomy Compared to Lobectomy for Stage IA Lung Cancer.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSegmentectomy has become the new standard of care for selected patients with stage IA1-2 non-small cell lung cancer (NSCLC). For stage IA3 NSCLC, lobectomy is indicated. This study aims to compare the outcome after segmentectomy and lobectomy in patients with stage IA3 NSCLC.
methodsWe retrospectively reviewed all patients undergoing surgery for NSCLC in our center between 2013 and 2023. We identified all patients who underwent segmentectomy or lobectomy for pathological stage IA3 tumors. Survival was calculated from the date of surgery until last follow- up. Univariate analysis was performed to study the impact on overall survival (OS) and disease-free survival (DFS) of clinical variables.
resultsWe identified fifty-nine patients undergoing surgery for stage IA3 NSCLC. Twenty- seven (28%) patients underwent segmentectomy and sixty-eight (72%) patients underwent lobectomy. Median age was 68 years (47-85). Median FEV1 was 74% (39-140), median DLCO was 67% (28-128). Surgery was performed by VATS in most cases (91%). There was no difference in age and lung function between the lobectomy and segmentectomy groups. Five-year OS was 67%. 5-year DFS was 63%. Five-year DFS was significantly worse in patients who underwent segmentectomy compared to lobectomy (37% vs. 72%, p = 0.040). There was no difference in 5-year OS (56% vs. 69%, p = 0.56).
conclusionSegmentectomy is associated with significantly worse disease-free survival compared to lobectomy in our cohort of patients with stage IA3 NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.